Idorsia Ltd. · SIX:IDIA
Idorsia — Technical Presentation (June 2021)
54 slides from Idorsia's technical presentation, Jun 28, 2021
Slide 1: Phase 3 investigation of selatogrel in suspected AMI
Phase 3 investigation of selatogrel in suspected AMI Investor webcast – June 2021
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: Jean-Paul Clozel, Chief Executive Officer
Jean-Paul Clozel Chief Executive Officer 3 Investor webcast – June 2021
Slide 4: Our Strategic Priorities
Our Strategic Priorities Our mid-term key priorities to 2 Build a world-class commercial organization achieve long-term 3 Bring Idorsia to success: sustainable profitability 1 Deliver at least three products to market 4 Fuel our pipeline with new discoveries 5 Utilize state-of-the-art technologies t
Slide 5: Clinical development pipeline
Insomnia Clinical development pipeline Daridorexant Fabry disease Dual orexin receptor Resistant antagonist hypertension Lucerastat Status: Under review with management Glucosylceramide FDA/EMA Systemic lupus synthase inhibitor erythematosus Aprocitentan* Status: Phase 3 Suspected acute Dual endothe
Slide 6: Acute myocardial infarctions (AMI)
Acute myocardial infarctions (AMI) Heart attack can occur in: All ages. All ethnicities. All genders. 1/3 of deaths in developed nations can be attributed 80% of deaths caused by cardiovascular disease are due to heart attack to heart attack and stroke 1st heart Recurring 800,000 attack heart people
Slide 7: My personal experience
My personal experience 7 Investor webcast – June 2021
Slide 8: Martine Clozel, Chief Scientific Officer
Martine Clozel Chief Scientific Officer 8 Investor webcast – June 2021
Slide 9: AMI & P2Y12 receptor antagonists
AMI & P2Y12 receptor antagonists 9 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 10: P2Y12 receptor antagonist class has
P2Y12 receptor antagonist class has: Established efficacy Well known safety profile 10 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 11: Unmet medical need in AMI
Unmet medical need in AMI Onset of AMI symptoms Admission to hospital for treatment Likelihood of death from AMI (pre-hospital admission) Heart attack in progress 11 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 12: Unmet medical need in AMI
Unmet medical need in AMI Onset of AMI symptoms Admission to hospital for treatment Likelihood of death from AMI (pre-hospital admission) ~20% prior to admission Heart attack in progress 12 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 13: Unmet medical need in AMI
Unmet medical need in AMI Onset of AMI symptoms Admission to hospital for treatment Likelihood of death from AMI (pre-hospital admission) ~20% prior to admission ~10% during admission Heart attack in progress 13 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 14: Target profile to fill the gap
Target profile to fill the gap Rapid absorption Short duration of action Suitable safety profile for and onset of action and rapid elimination use outside a hospital 14 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 15: Idorsia's innovation
Idorsia’s innovation Selatogrel Heart attack in progress Selatogrel is investigational, in development and not approved or marketed in any country. 15 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 16: Thrombotic activity and the role of P2Y12 receptor antagonists
Thrombotic activity and the role of P2Y12 receptor antagonists 16 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 17: Thrombus formation
Thrombus formation Platelet Mixed: Fibrin rich Platelet rich & Fibrin < 3 hours 3-6 hours > 6 hours Thrombosis Silvain, J., et al. J Am Coll Cardiol. 2011:57(12) 17 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 18: Thrombus formation
Thrombus formation Platelet Mixed: Fibrin rich Platelet rich & Fibrin < 3 hours 3-6 hours > 6 hours Thrombosis P2Y12 receptor antagonists may have a role at AMI symptom onset Silvain, J., et al. J Am Coll Cardiol. 2011:57(12) 18 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 19: The chemical and biochemical properties of selatogrel
The chemical and biochemical properties of selatogrel Selatogrel is investigational, in development and not approved or marketed in any country. 19 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 20: Selatogrel properties
Selatogrel properties ‘Fast’ onset of action ‘Short’ duration of action Potent and highly selective antagonist of the P2Y12 receptor Selatogrel is investigational, in development and not approved or marketed in any country. 20 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 21: Selatogrel properties: plasma concentration profiles
Selatogrel properties Plasma concentration time profiles by dose (linear) 1100 1 mg (n=6) 2 mg (n=6) 4 mg (n=6) 1000 ‘Fast’ onset Selatogrel concentration (ng/mL) 900 8 mg (n=6) 16 mg (n=6) 32 mg (n=6) 800 of action 700 600 500 400 300 ‘Short’ duration 200 of action 100 0 0 1 2 3 4 5 6 7 8 9 10 11 1
Slide 22: Selatogrel properties: plasma concentration profiles
Selatogrel properties Plasma concentration time profiles by dose (linear) 1100 1 mg (n=6) 2 mg (n=6) 4 mg (n=6) 1000 ‘Fast’ onset Selatogrel concentration (ng/mL) 900 8 mg (n=6) 16 mg (n=6) 32 mg (n=6) 800 of action 700 600 500 400 300 ‘Short’ duration 200 of action 100 0 0 1 2 3 4 5 6 7 8 9 10 11 1
Slide 23: Selatogrel properties: plasma concentration profiles
Selatogrel properties Plasma concentration time profiles by dose (linear) 1100 1 mg (n=6) 2 mg (n=6) 4 mg (n=6) 1000 ‘Fast’ onset Selatogrel concentration (ng/mL) 900 8 mg (n=6) 16 mg (n=6) 32 mg (n=6) 800 of action 700 600 500 400 300 ‘Short’ duration 200 of action 100 0 0 1 2 3 4 5 6 7 8 9 10 11 1
Slide 24: Selatogrel properties
Selatogrel properties ‘Fast’ onset of action Flow Flow Blood flow (Doppler) ‘Short’ duration of action Occluded Time (min) 24:45 37:07 49:33 Potent and highly selective antagonist of the P2Y12 receptor Preclinical data from a modified Folts model in guinea pigs Selatogrel is investigational, in deve
Slide 25: Selatogrel properties
Selatogrel properties Vessel injury ‘Fast’ onset of action Flow Flow Blood flow (Doppler) ‘Short’ duration of action Occluded Time (min) 24:45 37:07 49:33 Potent and highly Full occlusion, then dislodgement selective antagonist Cyclic Flow Variations of the P2Y12 receptor Preclinical data from a mod
Slide 26: Selatogrel properties
Selatogrel properties Selatogrel 30 µg/kg s.c. ‘Fast’ onset 10’ of action Flow Flow Blood flow (Doppler) ‘Short’ duration of action Occluded Time (min) 24:45 37:07 49:33 Potent and highly Full occlusion, then dislodgement selective antagonist Cyclic Flow Variations of the P2Y12 receptor Preclinical
Slide 27: Selatogrel properties: blood loss versus ticagrelor
Selatogrel properties Effects of selatogrel and ticagrelor on blood loss in anesthetized Wistar rats 4 n=9-35 ‘Fast’ onset Surgical blood loss (g) 3 of action 2 1 ‘Short’ duration Selatogrel of action Ticagrelor 0 Vehicle Low Mid High Dose Rat thrombosis model. Dose dependent surgical blood loss aft
Slide 28: Unlocking the full potential of selatogrel
Unlocking the full potential of selatogrel Selatogrel is investigational, in development and not approved or marketed in any country. 28 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 29: Unlocking the full potential of selatogrel
Unlocking the full potential of selatogrel ‘Fast’ onset ‘Short’ duration of action of action Potent and highly Suitable for selective antagonist subcutaneous of the P2Y12 receptor injection Selatogrel is investigational, in development and not approved or marketed in any country. 29 Phase 3 investig
Slide 30: Unlocking the full potential of selatogrel
Unlocking the full potential of selatogrel Self-administration Heart attack in progress Selatogrel is investigational, in development and not approved or marketed in any country. 30 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 31: Guy Braunstein, Head of Global Clinical Development
Guy Braunstein Head of Global Clinical Development 31 Investor webcast – June 2021
Slide 32: What happens with AMI today?
What happens with AMI today? Patient delay Further delay due to failure while waiting to recognize for emergency and react services Onset of AMI Patient calls for First medical Emergency medical symptoms emergency service or contact care follow-up at travels to hospital hospital Heart attack in prog
Slide 33: Early intervention is key to improve outcome
Early intervention is key to improve outcome Pre-requisites for this to happen Symptom Fast-acting Easy-to-use recognition treatment Safe product Short duration Selatogrel is investigational, in development and not approved or marketed in any country. 33 Phase 3 investigation of selatogrel for suspe
Slide 34: The groundwork to prepare for a registration study
The groundwork to prepare for a registration study for this novel concept Selatogrel is investigational, in development and not approved or marketed in any country. 34 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 35: Key learnings from clinical pharmacology studies
Key learnings from clinical pharmacology studies Pharmacodynamics: Inhibition of platelet aggregation (IPA) with 16 mg selatogrel Selatogrel (ng/mL) IPA (%) Time (h) Selatogrel is investigational, in development and not approved or marketed in any country. 35 Phase 3 investigation of selatogrel for
Slide 36: Phase 2 clinical development
Phase 2 clinical development Safety Selatogrel was tested in patients with chronic coronary syndrome and in Pharmacokinetics patients experiencing an AMI to validate PK and PD profiles observed in clinical pharmacology studies Pharmacodynamics • Subcutaneous administration by a healthcare profession
Slide 37: Phase 2 clinical development
Phase 2 clinical development Selatogrel has a rapid PD effect following subcutaneous injection Platelet reactivity unit (PRU) Data from chronic coronary syndrome study – Consistent with results from AMI study Hours post-injection Selatogrel is investigational, in development and not approved or mark
Slide 38: Safety in patients with chronic coronary syndrome
Safety in patients with chronic coronary syndrome 8 mg selatogrel 16 mg selatogrel Placebo Treatment-emergent AEs*, n (%) (N=114) (N=115) (N=116) Patients with ≥1 AE 36 (32) 26 (23) 25 (22) Patients with serious AEs 0 0 0 Most frequent AEs (≥3 subjects) Dyspnoea 6 (5) 10 (9) 0 Median duration, h 2.4
Slide 39: Early intervention is key to improve outcome
Early intervention is key to improve outcome Pre-requisites for this to happen Symptom Fast-acting Easy-to-use recognition treatment Safe product Short duration 16 mg dose selected for further investigation in Phase 3 Selatogrel is investigational, in development and not approved or marketed i
Slide 40: The selatogrel-autoinjector combination product
The selatogrel-autoinjector combination product – a device designed for emergency use Selatogrel is investigational, in development and not approved or marketed in any country. 40 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 41: The selatogrel-autoinjector combination product
The selatogrel-autoinjector combination product – a device designed for emergency use Robust Reliable Easy-to-use Emergency ready Selatogrel is investigational, in development and not approved or marketed in any country. 41 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 42: The selatogrel-autoinjector combination product
The selatogrel-autoinjector combination product – a device designed for emergency use Robust Reliable Easy-to-use Emergency ready The selatogrel-autoinjector has been found to be safe and to perform as intended for the intended users, uses, and use environments in the planned Phase 3 clinical study
Slide 43: Early intervention is key to improve outcome
Early intervention is key to improve outcome Pre-requisites for this to happen Symptom Fast-acting Easy-to-use recognition treatment Safe product Short duration Selatogrel is investigational, in development and not approved or marketed in any country. 43 Phase 3 investigation of selatogrel f
Slide 44: Patient training
Patient training Training-specific material mirrored across all regions 1 When to inject? Recognize the symptoms of AMI How to and 2 where to inject? Instruction on use of the autoinjector Selatogrel is investigational, in development and not approved or marketed in any country. 44 Phase 3 investiga
Slide 45: Pre-requisites for early intervention in place
Pre-requisites for early intervention in place Time to prove the concept in a large registration study Symptom Fast-acting Easy-to-use recognition treatment Safe product Short duration Selatogrel is investigational, in development and not approved or marketed in any country. 45 Phase 3 inv
Slide 46: Selatogrel Outcome Study in suspected AMI (SOS-AMI)
Selatogrel Outcome Study in suspected Acute Myocardial Infarction “SOS-AMI” Putting selatogrel in the hands of patients Selatogrel is investigational, in development and not approved or marketed in any country. 46 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 47: SOS-AMI – Phase 3 registration study
SOS-AMI – Phase 3 registration study Concept Patient Onset of Patient recognizes first self-injects the Diagnosis symptoms symptoms study drug and calls emergency Selatogrel is investigational, in development and not approved or marketed in any country. 47 Phase 3 investigation of selatogrel for sus
Slide 48: Who will we enroll in the study
Who will we enroll in the study Patients at high-risk of a repeat AMI in the next 12 months Selatogrel is investigational, in development and not approved or marketed in any country. 48 Phase 3 investigation of selatogrel for suspected AMI | 28 Jun 2021
Slide 49: SOS-AMI: Operationalizing the study
SOS-AMI: Operationalizing the study 14,000 patients planned to be randomized Study design Screening phase Observation phase Within 4 weeks from hospital discharge Trainer follow-up, week 2, 1 month, then at 3 months intervals Patient journey High risk Training and Randomization Recognize symptoms an
Slide 50: SOS-AMI: Operationalizing the study
SOS-AMI: Operationalizing the study 14,000 patients planned to be randomized Study design Screening phase Observation phase Within 4 weeks from hospital discharge Trainer follow-up, week 2, 1 month, then at 3 months intervals Patient journey High risk Training and Randomization Recognize symptoms an
Slide 51: Data flow in SOS-AMI
Data flow in SOS-AMI Primary efficacy Primary safety endpoints: endpoints: Death, AMI Severe Bleedings Clinical event committee (blinded independent adjudication) Ranking by severity Ranking of bleeding by severity using 6-point scale from according to BARC definition “no event” up to “death” BARC:
Slide 52: What happens with AMI today?
What happens with AMI today? Waiting for emergency services Patient delay due to failure to recognize and react Onset of AMI Patient calls for First medical Emergency medical symptoms emergency service or contact care follow-up at travels to hospital hospital Heart attack in progress The longer the
Slide 53: How could AMI be managed in the future?
How could AMI be managed in the future? Onset of AMI Self-administer Patient calls for First medical Emergency medical symptoms selatogrel using emergency service or contact care follow-up at autoinjector at travels to hospital hospital symptom onset Slowing or stopping Early Heart intervention atta
Slide 54: Quote from Dr Deepak L. Bhatt, SOS-AMI Steering Committee
“Despite the success of chronic treatment with P2Y12 receptor antagonists, patients are still suffering repeat heart attacks. The method of administration or the delayed onset of effect means that there remains a distinct unmet medical need in the treatment of AMI. The idea for patients to self-inje